Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384986 | 0.95 | MEN1 (0.34) | MEN1KMT2AALDH1A1POLBCYP4F2 | |
| SCHEMBL27906278 | 0.84 | MEN1 (0.33) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL15114542 | 0.81 | CYP2C19 (0.33) | ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL34476196 | 0.80 | NPSR1 (0.35) | MEN1KMT2AALDH1A1POLBCYP4F2 | |
| SCHEMBL7387048 | 0.78 | CYP4F2 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL15114545 | 0.76 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL7604952 | 0.75 | CYP4F2 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL15114552 | 0.71 | PPARG (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL16370687 | 0.70 | ALDH1A1 (0.36) | ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL11668069 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127223-A | Use of nanoparticle compositions as heat transfer fluids in batteries or other electrical device systems | 赢创运营有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-1482022-B1 | Pyrans as liquid crystals | MERCK PATENT GMBH (DE) | 2010-06-09 | — | — | EP | disclosed |
| US-6974607-B2 | Pyrans as liquid crystals | MERCK PATENT GMBH (DE) | 2005-12-13 | — | — | US | disclosed |
| US-20050142300-A1 | PYRANS AS LIQUID CRYSTALS | RAMBUS, INC. (US) | 2005-06-30 | — | — | US | disclosed |
| EP-1482022-A1 | Pyrans as liquid crystals | MERCK PATENT GmbH (DE) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142300-A1 | PYRANS AS LIQUID CRYSTALS | CYP4F3, SF3A3, NCAPD3 | MEN1 2628/4885KMT2A 4307/4885ALDH1A1 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.